Massimo Terzolo
Impact in
- Endocrinology, Diabetes and Metabolism top 0.05%
- Pituitary Gland Disorders and Treatments
- Hormonal Regulation and Hypertension
- Adrenal Hormones and Disorders
- Growth Hormone and Insulin-like Growth Factors
- Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism
Papers in
- Surgery 159
- Adrenal and Paraganglionic Tumors 157
-
- Pituitary Gland Disorders and Treatments 106
- Hormonal Regulation and Hypertension 55
- Adrenal Hormones and Disorders 29
- Growth Hormone and Insulin-like Growth Factors 20
- Co-authors
- Giuseppe Reimondo (84 shared papers)Alberto Angeli (68 shared papers)Martin Faßnacht (31 shared papers)G. Osella (30 shared papers)Silvia Bovio (24 shared papers)Alfredo Berruti (35 shared papers)Anna Pia (35 shared papers)P. Paccotti (43 shared papers)
- Journals
- The Journal of Clinical Endocrinology & Metabolism (33 papers)European Journal of Endocrinology (26 papers)Clinical Endocrinology (10 papers)Frontiers in Endocrinology (6 papers)Cancers (6 papers)
- Partner nations
- ItalyGermanyUnited States
In The Last Decade
Massimo Terzolo
251 papers receiving 12.0k citations
Massimo Terzolo's Hit Papers
Peers
Comparison fields: 5 of 129
- Endocrinology, Diabetes and Metabolism 5.9k
- Cancer Research 3.3k
- Surgery 8.3k
- Genetics 1.2k
- Behavioral Neuroscience 128
Countries citing papers authored by Massimo Terzolo
This map shows the geographic impact of Massimo Terzolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Terzolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Terzolo more than expected).
Fields of papers citing papers by Massimo Terzolo
This network shows the impact of papers produced by Massimo Terzolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Terzolo. The network helps show where Massimo Terzolo may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Terzolo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 258 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors Hit paper breakdown → | 2016 | 1016 |
| 2 | European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors Hit paper breakdown → | 2018 | 591 |
| 3 | Prevalence of adrenal incidentaloma in a contemporary computerized tomography series Hit paper breakdown → | 2006 | 511 |
| 4 | Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma Hit paper breakdown → | 2008 | 490 |
| 5 | AME Position Statement on adrenal incidentaloma Hit paper breakdown → | 2011 | 366 |
| 6 | European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors Hit paper breakdown → | 2023 | 304 |
| 7 | 2002 | 264 | |
| 8 | Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study Hit paper breakdown → | 2015 | 257 |
| 9 | Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2020 | 256 |
| 10 | 2006 | 225 | |
| 11 | 2005 | 213 | |
| 12 | 2000 | 210 | |
| 13 | 1997 | 195 | |
| 14 | 2014 | 179 | |
| 15 | 1994 | 161 | |
| 16 | 1998 | 161 | |
| 17 | 2010 | 134 | |
| 18 | 2005 | 128 | |
| 19 | 2011 | 127 | |
| 20 | 2008 | 121 |
About Massimo Terzolo
Massimo Terzolo is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cancer Research, Genetics and Endocrine and Autonomic Systems, having authored 258 papers that have together received 12.3k indexed citations. Recurring topics across this work include Adrenal and Paraganglionic Tumors (157 papers), Pituitary Gland Disorders and Treatments (106 papers), Cancer, Hypoxia, and Metabolism (66 papers), Hormonal Regulation and Hypertension (55 papers), Adrenal Hormones and Disorders (29 papers), Glioma Diagnosis and Treatment (27 papers), Growth Hormone and Insulin-like Growth Factors (20 papers) and Circadian rhythm and melatonin (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (5.9k citations), Cancer Research (3.3k citations), Surgery (8.3k citations), Genetics (1.2k citations) and Behavioral Neuroscience (128 citations). Massimo Terzolo has collaborated with scholars based in Italy, Germany and United States. Frequent co-authors include Giuseppe Reimondo, Alberto Angeli, Martin Faßnacht, G. Osella, Silvia Bovio, Alfredo Berruti, Anna Pia, P. Paccotti, Fulvia Daffara and Alfredo Berruti. Their work appears in journals such as The Journal of Clinical Endocrinology & Metabolism, European Journal of Endocrinology, Clinical Endocrinology, Frontiers in Endocrinology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.